source
- Takeda drops its second celiac disease candidate, TAK-101, after unimpressive phase 2 resultsTakeda said it is halting development of TAK-101, its second candidate for celiac disease, after a phase 2 study failed to meet expectations. TAK-101 is a nanoparticle that carries gliadin, a glut…
- Biopharma layoffs in 2026 often marred by impersonal and poorly timed communicationsOver 50 biopharma companies have announced workforce cuts or plan to do so in 2026. According to a BioSpace survey, the manner in which these layoffs are communicated can leave a lasting negative i…